Welcome to our dedicated page for Applied Therapeutics SEC filings (Ticker: APLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Applied Therapeutics, Inc. (APLT) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings give detailed insight into how the clinical-stage biopharmaceutical company reports its financial condition, pipeline progress, capital structure, and material corporate events related to its rare disease programs.
Investors use Forms 10-K and 10-Q to review Applied Therapeutics’ audited and quarterly financial statements, research and development spending, license and collaboration arrangements, and risk factor disclosures tied to its lead drug candidate govorestat (AT-007) and other programs. These reports also describe the company’s focus on CNS rare metabolic diseases, including Classic Galactosemia, CMT-SORD, and PMM2-CDG, and summarize key regulatory designations such as Orphan Drug and Rare Pediatric Disease status.
Form 8-K current reports are especially important for APLT. Recent 8-K filings describe the Agreement and Plan of Merger with Cycle Group Holdings Limited, including the tender offer structure, cash consideration and non-tradeable contingent value rights (CVRs), as well as the board’s recommendation to stockholders. Other 8-Ks cover the initiation of a strategic alternatives review, workforce reductions, at-the-market equity offering agreements, Nasdaq bid price notifications and listing transfers, leadership changes, and quarterly earnings press releases.
Users interested in insider and security-holder activity can also reference ownership-related filings (such as Forms 3, 4, and 5 when available) to understand how directors, officers, and major holders transact in APLT securities around key clinical or corporate milestones.
On Stock Titan, these Applied Therapeutics filings are updated in near real time as they appear on EDGAR. AI-powered tools can help summarize lengthy 10-K and 10-Q reports, highlight material sections of 8-Ks related to the Cycle merger, strategic reviews, or Nasdaq notices, and make it easier to interpret complex capital structure and contingent value right provisions. This allows readers to quickly grasp what each filing means for APLT’s financial position, regulatory path for govorestat, and the status of the proposed acquisition.
Applied Therapeutics director Stacy J. Kanter filed an insider report reflecting changes to her holdings tied to the company’s merger with Cycle Group Holdings Limited and AT2B, Inc. Each share of Applied Therapeutics common stock was converted into the right to receive $0.088 in cash per share, plus one non-tradeable contingent value right under a contingent value rights agreement.
According to the filing, common shares tendered by Kanter were exchanged for this merger consideration, her restricted stock units fully vested and were converted into the same package, and her stock options with exercise prices at or above the cash amount were fully vested and then cancelled at the merger’s effective time for no consideration.
Applied Therapeutics Chief Commercial Officer Hooks Corwin Dale reported merger-related equity transactions and a prior grant of restricted stock units (RSUs). On December 19, 2025, he received 312,500 RSUs under the 2019 Equity Incentive Plan, vesting upon a Change in Control or June 19, 2026, if he remained in service.
A merger with Cycle Group Holdings Limited and AT2B, Inc. became effective on January 28, 2026. At that time, each share of Applied Therapeutics common stock and each RSU was cancelled and converted into the right to receive $0.088 per share in cash plus one non-tradeable contingent value right.
On February 3, 2026, Dale reported the disposition of 862,500 shares of common stock and a further 5,753 shares, all exchanged for the merger consideration, leaving him with no directly held shares. The filing also notes a correction of earlier administrative understatement of his total holdings.
Applied Therapeutics officer Constantine Chinoporos reported equity changes tied to a merger and prior equity awards. On December 19, 2025, he received 437,500 compensatory RSUs at $0 under the 2019 Equity Incentive Plan, each RSU representing one share that would vest upon a change in control or by June 19, 2026, if he remained in service.
The filing also corrects earlier administrative errors that had overstated his total holdings. Following completion of a tender offer and merger effective January 28, 2026, each Applied Therapeutics common share was cancelled and converted into $0.088 in cash plus one non‑tradeable contingent value right. On February 3, 2026, he reported disposition of 1,000,000 shares and a final 57,111‑share adjustment, leaving zero shares directly owned after the merger consideration was received.
Applied Therapeutics, Inc. completed a merger in which each common share was converted into cash and a contingent value right. Under the Merger Agreement with Cycle Group Holdings Limited and AT2B, INC., each outstanding share became entitled to receive $0.088 in cash per share plus one non-tradeable contingent value right.
Director Skyler Jay S tendered all common shares for this merger consideration and no longer holds Applied Therapeutics stock. In addition, several stock options with exercise prices at or above the cash amount were fully vested and then cancelled at the merger’s effective time without any payment.
Applied Therapeutics, Inc. insider filing shows equity converted and cancelled in a completed merger. Director and Interim Chief Executive Officer/Chief Financial Officer Leslie D. Funtleyder received 1,187,500 restricted stock units on 12/19/2025 that would vest on a change in control or by June 19, 2026.
Under a merger with Cycle Group Holdings Limited and AT2B, Inc., effective January 28, 2026, each Applied Therapeutics common share was converted into the right to receive
Following these transactions reported on 02/03/2026, Funtleyder reported zero remaining Applied Therapeutics common shares or stock options held directly.
Applied Therapeutics Chief Medical Officer Bailey Evan Prescott reported equity changes tied to the company’s sale. On December 19, 2025, Prescott received 437,500 compensatory RSUs at $0 under the 2019 Equity Incentive Plan, vesting upon a change in control or by June 19, 2026.
Under a merger with Cycle Group Holdings Limited, effective January 28, 2026, each common share was converted into $0.088 in cash plus one non-tradeable contingent value right. Prescott disposed of 1,235,915 common shares for this merger consideration, and remaining 60,901 shares were also exchanged. Two out-of-the-money stock options for 19,531 and 4,883 shares, both with a $1.05 exercise price, were fully vested then cancelled for no consideration.
Applied Therapeutics director Teena Lerner reported the conversion and cancellation of her equity holdings in connection with a completed merger. Under a Merger Agreement with Cycle Group Holdings Limited and AT2B, INC., a tender offer was followed by a merger effective as of January 28, 2026.
At the effective time, each common share was cancelled and converted into the right to receive $0.088 in cash per share plus one non‑tradeable contingent value right. All RSUs vested and were converted into the same merger consideration. Out‑of‑the‑money stock options, including several grants listed in the filing, were fully vested then cancelled for no consideration, leaving Lerner with no remaining common stock or options.
FAQ
What is the current stock price of Applied Therapeutics (APLT)?
What is the market cap of Applied Therapeutics (APLT)?
